Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease

Journal of Internal Medicine

Volumn 265, Issue 5, 2009, Pages 593-603

  Duner P ^a   To, F ^a   Alm, R ^a   Goncalves I ^a   Fredrikson, G N ^a   Hedblad, B ^a   Berglund, G ^a   Nilsson, J ^a,b   Bengtsson, E ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Autoantibodies; Extracellular matrix; Fibronectin; Malondialdehyde

Indexed keywords

ALDEHYDE; AUTOANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; GROWTH FACTOR; LIPOPOLYSACCHARIDE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX PROTEIN; TENASCIN;

ACUTE HEART INFARCTION; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL CULTURE; CLINICAL STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MODIFICATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIPID OXIDATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUDDEN DEATH; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANIMALS; ARTERIES; ATHEROSCLEROSIS; AUTOANTIBODIES; BLOTTING, WESTERN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, LDL; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MALONDIALDEHYDE; MICE; MIDDLE AGED;

EID: 64249130241     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02067.x     Document Type: Article

References (36)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 95.
2. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001 4 : 142 7.
3. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003 14 : 421 30.
4. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation 1997 95 : 1062 71.
5. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000 247 : 371 80.
6. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clin Chim Acta 2004 2 : 1 8.
7. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002 8 : 1218 26.
8. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006 6 : 508 19.
9. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005 25 : 18 28.
10. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995 92 : 821 5.
11. Ameli S, Hultgardh-Nilsson A, Regnstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996 16 : 1074 9.
12. George J, Afek A, Gilburd B et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998 138 : 147 52.
13. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001 21 : 108 14.
14. Fredrikson GN, Soderberg I, Lindholm M et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003 23 : 879 84.
15. Chyu KY, Zhao X, Reyes OS et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun 2005 338 : 1982 9.
16. Gustafsson M, Boren J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004 15 : 505 14.
17. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007 116 : 1832 44.
18. Skalen K, Gustafsson M, Rydberg EK et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002 417 : 750 4.
19. Greilberger J, Schmut O, Jurgens G. In vitro interactions of oxidatively modified LDL with type I, II, III, IV, and V collagen, laminin, fibronectin, and poly-D-lysine. Arterioscler Thromb Vasc Biol 1997 17 : 2721 8.
20. van der Hoek YY, Sangrar W, Cote GP, Kastelein JJ, Koschinsky ML. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arterioscler Thromb Vasc Biol 1994 14 : 1792 8.
21. Fredrikson GN, Berglund G, Alm R, Nilsson JA, Shah PK, Nilsson J. Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide. J Lipid Res 2006 47 : 2049 54.
22. Fredrikson GN, Hedblad B, Berglund G et al. Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003 23 : 872 8.
23. Goncalves I, Moses J, Dias N et al. Changes related to age and cerebrovascular symptoms in the extracellular matrix of human carotid plaques. Stroke 2003 34 : 616 22.
24. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000 17 : 299 307.
25. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989 86 : 1372 6.
26. Slatter DA, Paul RG, Murray M, Bailey AJ. Reactions of lipid-derived malondialdehyde with collagen. J Biol Chem 1999 274 : 19661 9.
27. Song KS, Kim HK, Shim W, Jee SH. Plasma fibronectin levels in ischemic heart disease. Atherosclerosis 2001 154 : 449 53.
28. Orem C, Durmus I, Kilinc K et al. Plasma fibronectin level and its association with coronary artery disease and carotid intima-media thickness. Coron Artery Dis 2003 14 : 219 24.
29. Beezhold DH, Personius C. Fibronectin fragments stimulate tumor necrosis factor secretion by human monocytes. J Leukoc Biol 1992 51 : 59 64.
30. Oorni K, Pentikainen MO, Ala-Korpela M, Kovanen PT. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res 2000 41 : 1703 14.
31. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000 43 : 550 7.
32. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004 110 : 2047 52.
33. Strom A, Fredrikson GN, Schiopu A et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 2006 190 : 298 305.
34. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007 194 : e188 92.
35. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 2004 104 : 11 18.
36. Babaev VR, Porro F, Linton MF, Fazio S, Baralle FE, Muro AF. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 2008 197 : 534 40.